Research programme: PPAR alpha/gamma agonists - MaxoCore Pharmaceuticals

Drug Profile

Research programme: PPAR alpha/gamma agonists - MaxoCore Pharmaceuticals

Alternative Names: MC-3002; PPAR alpha/gamma agonists research programme - MaxoCore Pharmaceuticals

Latest Information Update: 11 Jan 2011

Price : $50

At a glance

  • Originator MaxoCore Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Atherosclerosis; Hypercholesterolaemia; Metabolic syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 11 Jan 2011 This programme is in active development
  • 07 Dec 2010 Research programme: PPAR alpha/gamma agonists - MaxoCore Pharmaceuticals is available for licensing as of 07 Dec 2010. http://www.maxocore.com
  • 14 Jul 2004 The programme is available for licensing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top